Fangsheng Pharmaceutical (603998.SH): Indobufen tablets, etc. to be selected for centralized procurement

Zhitongcaijing · 1d ago

Zhitong Finance App News, Fangsheng Pharmaceutical (603998.SH) issued an announcement. Recently, the company participated in the bid for the 12th batch of centralized procurement of state-organized drugs. According to the “Announcement on the Results of the 12th Batch of Centralized Volume Procurement of National Organization Drugs” issued by the Joint Procurement Office of State Organization Drugs on July 31, 2026, the company's product indolebufen tablets and bisoprolol amlodipine tablets, a wholly-owned subsidiary of the company, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. are to be selected for this centralized procurement.

This centralized drug procurement is the 12th batch of centralized procurement of national drugs organized by the state. In terms of implementation, medical institutions are required to prioritize the use of selected varieties from centralized procurement and ensure that the agreed procurement volume is completed. The price of the product to be selected this time has decreased to a certain extent compared to the original price. If the company subsequently signs a procurement contract and implements it, it will help the above products to quickly open up the domestic sales market, increase market share, promote the further development of the company's formulation business, enhance the company's brand influence, and have a positive impact on the company's future operations.